
    
      This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce
      facial redness typically associated with rosacea. Approximately 25 subjects will be enrolled.

      Subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (BL,
      W1, W2, W4).
    
  